[
  {
    "ts": null,
    "headline": "Viking Therapeutics: The Obesity Drugs Gold Rush Is Far From Over",
    "summary": "VKTX is a top obesity drug contender with $700M liquidity and dual injectable/oral pipeline.",
    "url": "https://finnhub.io/api/news?id=a555af6591f832117a36a03604014ec0fc611b504293435501abc14846ca6fd2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767434400,
      "headline": "Viking Therapeutics: The Obesity Drugs Gold Rush Is Far From Over",
      "id": 137973561,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1393991964/image_1393991964.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "VKTX is a top obesity drug contender with $700M liquidity and dual injectable/oral pipeline.",
      "url": "https://finnhub.io/api/news?id=a555af6591f832117a36a03604014ec0fc611b504293435501abc14846ca6fd2"
    }
  }
]